Consider starting metformin and a second-line medicine at diagnosis if the HbA1c is 8%; SGLT2i (GLP1RA) is the preferred second-line medicine for most patients with T2D.

Formal Recommendations

Recommendation & Evidence

Recommendation Strength-

Evidence Level-

Recommendation direction

People newly diagnosed with type 2 diabetes and HbA1c about 8%

Consider metformin plus a second-line agent at diagnosis, preferably an SGLT2 inhibitor or GLP-1 receptor agonist

Metformin alone

Not reported

Evidence No.-

Evidence-

Evidence Level-

Recommendation Strength-

Statement TypeFormal Recommendations

Guideline NameSamoa MOH National Diabetes Guidelines

Guideline No.2-2024-035E

AuthorAlec Ekeroma

Guideline TypeGuideline

Year2024

OrganizationMinistry of Health Samoa

RegionOceania

CountrySamoa

Conflict of InterestNo

DOI无

Target Population所有糖尿病患者（包括1型糖尿病、2型糖尿病、妊娠期糖尿病、儿童及青少年），特别是萨摩亚及太平洋人群，包括高危人群（超重/肥胖、有家族史、既往糖尿病史等）

Journal无

Recommendation Strength MethodologyNone

Evidence Level MethodologyNone

Living GuidelineNo

Rapid AdviceNo

UpdatedNo

Recommendation Count0

Reference Count50

Guideline TopicComprehensive

CategoriesPharmacologic Glycemic Management of Type 2 Diabetes

Created At2026-10-21 14:39:47

Updated At2026-10-21 14:39:47